Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 3/20 | 0.50 |
| ▸ | CCND1 | P24385 | 2/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11031045 | 0.92 | RAD52 (0.55) | SLC2A1PTK2CDK4CCND1MAPKAPK2 | |
| SCHEMBL11029599 | 0.91 | MAPKAPK2 (0.58) | SLC2A1CDK4CCND1MAPKAPK2BTK | |
| SCHEMBL11026741 | 0.90 | FYN (0.55) | SLC2A1CDK4CCND1MAPKAPK2BTK | |
| SCHEMBL11029346 | 0.90 | MAPKAPK2 (0.61) | SLC2A1CDK4CCND1MAPKAPK2BTK | |
| SCHEMBL11027433 | 0.89 | MAPKAPK2 (0.60) | SLC2A1CDK4CCND1MAPKAPK2BTK | |
| SCHEMBL11030051 | 0.87 | SLC2A1 (0.57) | SLC2A1CDK4MAPKAPK2EGFRMAP4K1 | |
| SCHEMBL11029146 | 0.87 | SLC2A1 (0.49) | SLC2A1CDK4CCND1MAPKAPK2EGFR | |
| SCHEMBL11030640 | 0.86 | PTK2 (0.59) | SLC2A1PTK2CDK4MAPKAPK2BTK | |
| SCHEMBL11030430 | 0.85 | BRD4 (0.63) | SLC2A1PTK2BTKEGFRBRD4 | |
| SCHEMBL11030064 | 0.85 | CHEK1 (0.56) | SLC2A1CDK4MAPKAPK2AURKACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | claimed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | claimed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | claimed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | SLC2A1 3662/4885PTK2 290/4885CDK4 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.